Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Jan 21;29(3):669–677. doi: 10.1523/JNEUROSCI.3921-08.2009

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2009 Society for Neuroscience 0270-6474/09/290669-09$15.00/0

PMC Copyright notice

Figure 6. — Treatment with Ant-AIP-2 cell-permeable peptide affects LTP but not LTD. A, The plots show that both in Ant-AIP-2-treated slices and in control slices, an LFS stimulating protocol (arrow) produces an LTD of fEPSP. The reported examples of fEPSPs before the LFS application and 60 min post-LFS reveal a similar LTD in control conditions (top traces) as well as in an Ant-AIP-2-treated slice (bottom traces). B, Time course of the normalized field potential (fEPSP) slope recorded in Ant-AIP-2-treated slices respect to nontreated (control) slices. The HFS stimulating protocol (arrow) produces an LTP of the fEPSP in control slices, whereas in Ant-AIP-2-treated slices, only a short-term potentiation can be observed. Note that the group treated with Ant-AIP-2 displays a reduced LTP in respect to control (p < 0.0001). Example traces of fEPSPs acquired before the application of the HFS protocol and 60 min post-HFS, in control conditions (top traces) and in an Ant-AIP-2-treated slice (bottom traces).